New Medicines to Fight Malaria
Novel Therapeutics to Target Parasite Cytochrome bc1
['FUNDING_R01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11114063
This research aims to discover and develop new, fast-acting medicines to treat and prevent malaria, a serious disease caused by parasites.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11114063 on ClinicalTrials.gov |
What this research studies
Our goal is to find better ways to fight malaria, especially as current treatments face challenges. We are focusing on developing new drugs that work quickly and can protect people from infection, even in areas where malaria is common. This involves targeting a specific part of the malaria parasite, called cytochrome bc1, which is essential for its survival. By developing new medicines that attack this target, we hope to create more effective tools for malaria elimination and eradication.
Who could benefit from this research
Good fit: Patients who could benefit from this research are those living in or traveling to malaria-prone regions, or individuals currently suffering from malaria infections.
Not a fit: Patients without malaria or not at risk of contracting it would not directly benefit from this specific drug development effort.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective, and faster-acting medications for treating and preventing malaria, especially important as parasites develop resistance to existing drugs.
How similar studies have performed: Other anti-malarial drugs, such as atovaquone + proguanil, have successfully targeted similar pathways, suggesting a promising approach for new drug development.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RISCOE, MICHAEL KEVIN — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: RISCOE, MICHAEL KEVIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.